Details for New Drug Application (NDA): 202564

NDA 202564 describes CLINDAMYCIN PHOSPHATE AND TRETINOIN, which is a drug marketed by Actavis Mid Atlantic, Encube, and Solaris Pharma Corp, and is included in three NDAs. It is available from three suppliers. Additional details are available on the CLINDAMYCIN PHOSPHATE AND TRETINOIN profile page.

The generic ingredient in CLINDAMYCIN PHOSPHATE AND TRETINOIN is clindamycin phosphate; tretinoin. There are fifty-five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the clindamycin phosphate; tretinoin profile page.

Summary for 202564

Tradename:	CLINDAMYCIN PHOSPHATE AND TRETINOIN
Applicant:	Actavis Mid Atlantic
Ingredient:	clindamycin phosphate; tretinoin
Patents:	0

Pharmacology for NDA: 202564

Physiological Effect

Decreased Sebaceous Gland Activity Neuromuscular Blockade

Suppliers and Packaging for NDA: 202564

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CLINDAMYCIN PHOSPHATE AND TRETINOIN	clindamycin phosphate; tretinoin	GEL;TOPICAL	202564	ANDA	Actavis Pharma, Inc.	0472-1790	0472-1790-30	1 TUBE in 1 CARTON (0472-1790-30) / 30 g in 1 TUBE
CLINDAMYCIN PHOSPHATE AND TRETINOIN	clindamycin phosphate; tretinoin	GEL;TOPICAL	202564	ANDA	Actavis Pharma, Inc.	0472-1790	0472-1790-60	1 TUBE in 1 CARTON (0472-1790-60) / 60 g in 1 TUBE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	GEL;TOPICAL			Strength	1.2%;0.025%
Approval Date:	Jun 12, 2015	TE:	AB1	RLD:	No

Complete Access Available with Subscription